Fox Run Management L.L.C. Acquires Shares of 2,627 United Therapeutics Corporation $UTHR

Fox Run Management L.L.C. acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,627 shares of the biotechnology company’s stock, valued at approximately $1,280,000.

Several other institutional investors and hedge funds have also bought and sold shares of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $553.14 on Wednesday. The firm has a market capitalization of $23.48 billion, a price-to-earnings ratio of 20.42, a P/E/G ratio of 1.77 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a fifty day moving average of $569.08 and a 200 day moving average of $520.18.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $6.63 EPS. Equities analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the completion of the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,712,246.04. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, June 8th. The shares were sold at an average price of $547.49, for a total value of $5,201,155.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,180,462.37. This represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 634,043 shares of company stock valued at $357,481,310. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Bank of America raised their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada cut their price target on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.